| Patent Number |
Title Of Patent |
Date Issued |
| RE35406 |
Barium titanium oxide-containing fluidizable cracking catalyst composition |
December 17, 1996 |
| A cracking catalyst composition comprising a zeolitic, crystalline aluminosilicate, a matrix material and a barium titanium oxide. The catalyst composition is particularly suitable for cracking metal-containing hydrocarbon feedstocks. |
| RE34996 |
Process for cracking metal-containing hydrocarbon feedstocks |
July 18, 1995 |
| A cracking catalyst composition comprising a zeolitic, crystalline aluminosilicate, a matrix material and a barium titanium oxide. The catalyst composition is particularly suitable for cracking metal-containing hydrocarbon feedstocks. |
| RE34242 |
Amino-oxazole compounds having dopaminergic activity |
May 4, 1993 |
| The present invention relates to new amino-thiazole and amino-oxazole derivatives of the general formula: ##STR1## wherein: R represents hydrogen, a lower alkyl group with 1 to 4 carbon atoms, a lower alkenyl group, a phenyl-alkyl (1-4 C), furanyl-alkyl (1-4 C) or thienyl-alkyl ( |
| RE32459 |
Viscosity modifiers for acrylamide polymers |
July 14, 1987 |
| An acrylamide polymer comprising acrylamide and a sufficient amount of cinnamic acid to substantially reduce the viscosity of the acrylamide polymer and solution. |
| RE31961 |
High solids pigment coating composition |
July 30, 1985 |
| A high solids pigmented coating composition is prepared from a curing agent and an ester diol binder which is a mixture of(a) 20-80 mole % of a compound having the general formula: ##STR1## where R.sub.1 represents the group formed by abstraction of the two carboxyl groups from a cyc |
| D328033 |
Rubber stopper |
July 21, 1992 |
|
| D325975 |
Cartridge for blood monitor |
May 5, 1992 |
|
| D325090 |
Cuvette |
March 31, 1992 |
|
| D323388 |
Tablet |
January 21, 1992 |
|
| 6013115 |
Fuel additive compositions for simultaneously reducing intake valve and combustion chamber depos |
January 11, 2000 |
| Engine deposits are reduced by adding an effective deposit-controlling amount of esteramine to hydrocarbon fuel. |
| 5618479 |
Process of making core-sheath filament yarns |
April 8, 1997 |
| In a yarn composed of core-sheath filaments with or without further monocomponent filaments, the core and the sheath of the core-sheath filaments are produced by extruding spinnable polymers, with at least almost all the core-sheath filaments having a complete sheath. Of all the core |
| 5581856 |
Process for the production of uncoated technical fabrics with low air permeability |
December 10, 1996 |
| Uncoated technical fabric is produced in a dense weave with low air permeability. The fabric contains polyamide filament yarns with a hot air shrinkage of 6 to 15% (determined at 160.degree. C.) and has an at least substantially symmetrical fabric construction. The fabric is adjusted to |
| 5578289 |
In vivo binding pair pretargeting |
November 26, 1996 |
| A method for in-vivo targeting a functional moiety in a patient by administering a targeting moiety coupled to an affinity component, wherein the targeting moiety has affinity for binding sites in a target area, and administering a binding partner to the affinity component coupled to a |
| 5518895 |
Device for detecting microorganisms using piezoelectric means |
May 21, 1996 |
| A device and method for detecting microorganisms in a specimen by culturing the specimen in a sealable specimen container with a culture medium and detecting microorganisms in the specimen-by measuring changes in pressure within the container caused by their metabolic activity during cul |
| 5514457 |
Textile structure for protective clothing |
May 7, 1996 |
| Textile structures, such as fabrics, knits, warp-knitted fabrics, stitch-bonded fabrics, thread structures, etc. for use in clothing which protects against stabbing, cutting, fragments and bullets, are produced from wrapped yarns. These yarns have a core of penetration resistant fibe |
| 5508073 |
Uncoated fabric for manufacturing air bags |
April 16, 1996 |
| Uncoated, tightly woven, synthetic filament yarn fabric for manufacturing an air bag. The fabric is manufactured from polyamide yarns having a filament linear density of less than 4 dtex. The air permeability of this fabric is <10 l/dm.sup.2 .multidot.min and its specific stiffness is |
| 5505890 |
Process for manufacturing cellulose acetate membranes |
April 9, 1996 |
| A dialysis membrane in the form of a hollow fiber with a continuous internal cavity is made of cellulose acetate or a cellulose acetate derivative. The membrane has a maximum screen coefficient of 0.04 for albumin with a molecular weight of 68,000. A dialysis membrane in the form of |
| 5496557 |
Article for the controlled delivery of an active substance, comprising a hollow space fully encl |
March 5, 1996 |
| An article for the controlled delivery of an active substance, comprising a hollow space fully enclosed by a wall and filled in full or in part with one or more active substances, which wall is made using a biodegradable polymeric material permeable to the active substance, wherein the w |
| 5495002 |
Tumor associated monoclonal antibody 123AV16 |
February 27, 1996 |
| This invention relates to transformed B-cell lines derived from peripheral blood B-cells of cancer patients actively immunized with autologous tumor antigen and the monoclonal antibodies they produce. These monoclonal antibodies can be used in both diagnostic procedures and therapy for h |
| 5493922 |
Liquid level sensing probe and control circuit |
February 27, 1996 |
| A method and apparatus for a liquid level sensor control circuit of a bioassay apparatus for controlling a position of a sampling probe with respect to a surface of a liquid in a container. The apparatus includes a sampling probe, an oscillator circuit coupled to the sampling probe for |
| 5484596 |
Active specific immunotherapy |
January 16, 1996 |
| This invention relates to a method of cancer therapy for treating human patients with resectable solid tumors to inhibit recurrence and formation of metastases, comprising surgically removing tumor tissue from a human cancer patient, treating the tumor tissue to obtain tumor cells, i |
| 5472434 |
Spike retainer system |
December 5, 1995 |
| A device for use in securing a venting pin or infusion spike to a delivery container such as a vial or bottle particularly when instilling a medicinal fluid to a patient through an intravenous set, catheter or similar fluid delivery set. |
| 5470659 |
Hollow fibers |
November 28, 1995 |
| A bundle of hollow fibers of uniform diameter, particularly for use in dialysis is formed of a plurality of parallel hollow fibres at least a part of which, prior to the formation of the bundle, is permanently undulated by means of interleaved undulating elements moving opposite the |
| 5468555 |
Yarn formed from core-sheath filaments and production thereof |
November 21, 1995 |
| In a yarn composed of core-sheath filaments with or without further monocomponent filaments, the core and the sheath of the core-sheath filaments are produced by extruding spinnable polymers, with at least almost all the core-sheath filaments having a complete sheath. Of all the core |
| 5464621 |
Canine corona virus vaccine |
November 7, 1995 |
| A live or inactivated canine corona virus vaccine is provided which is derived from a virus of the novel antigenic type of the canine corona virus strain I-743 (CNCM, Institut Pasteur, Paris). A method for the preparation of this vaccine and the use of said vaccine in protecting susc |
| 5462959 |
4-aryl-imidazole derivatives |
October 31, 1995 |
| The invention concerns a 4-aryl-imidazole derivative having the formula I ##STR1## wherein X is 0 or NOH,Y is NR.sub.3,Ar is a group selected from phenyl, naphthyl, tetrahydronaphthyl, and biphenyl,R is one to four substituents independently selected from hydrogen, hydroxy, lower alk |
| 5451668 |
Process for splitting off .DELTA..sup.4 -unsaturated uronic acid from glycosaminoglycans |
September 19, 1995 |
| Process for splitting off .DELTA..sup.4 -unsaturated uronic acid from glycosaminoglycan, in which the glycosaminoglycan is treated with an iodine solution or with a bleaching reagent, or with a combination thereof. |
| 5451373 |
Obstruction detector for a fluid flow line of a medical laboratory instrument |
September 19, 1995 |
| An apparatus for detecting obstructions of a flow line. A detector housing is provided having a cavity therein. The detector housing has first and second openings into the cavity. The flow line is attached to the detector housing establishing a flow path through the first opening, the ca |
| 5449765 |
DNA encoding amino acids 590-710 of glycoprotein gII of pseudorabies virus |
September 12, 1995 |
| The present invention is concerned with a pseudorabies virus (PRV) vaccine comprising a polypeptide of the PRV glycoprotein gII or a fragment thereof which was shown to be the site of interaction of PRV neutralizing antibodies. Vector vaccines capable to express a polynucleotide fragment |
| 5442003 |
Para-aramid dope of low degree of polymerization, para-aramid fiber and para-aramid pulp produce |
August 15, 1995 |
| A para-aramide dope of low degree of polymerization exhibiting an optical anisotropy containing 4-10% by weight of a para-aramide having an inherent viscosity of 1.0-2.5 dl/g and 2-10% by weight of an alkali metal chloride or an alkaline earth metal chloride in a polar amide solvent;a pa |
| 5441747 |
Stabilized solid pharmaceutical composition containing acid addition salts of a basic drug and a |
August 15, 1995 |
| Disclosed are stabilized dry chemical (e.g. pharmaceutical) compositions containing the water soluble acid addition salt of a poorly soluble basic compound (e.g. mianserin, apomorphine, chlorpromazine, imipramine, or promethazine); an excipient selected from the group consisting of m |
| 5433955 |
Site specific in vivo activation of therapeutic drugs |
July 18, 1995 |
| A method for site-specific in-vivo activation of a prodrug in an animal using an activator-targeting moiety conjugate to localize an activator at a predetermined site of use and a prodrug compound that is converted to an active drug in the presence of the activator. In the preferred embo |
| 5430187 |
Method for manufacturing dibenzylamine |
July 4, 1995 |
| The method for manufacturing dibenzylamine by reacting benzaldehyde and ammonia in the presence of hydrogen and a hydrogenation catalyst in an inert organic solvent is characterized by the fact that the reaction is conducted with an ammonia ratio of >0.5 mol per mol benzaldehyde and w |
| 5430063 |
Phenoxyphenyl derivatives, compositions thereof and methods for their use |
July 4, 1995 |
| The invention concerns a phenoxyphenyl compound having the formula ##STR1## wherein R is one or two halogen atoms; andA is CH.sub.2 NR.sub.1 R.sub.2 or 4,5-dihydro-1H-imidazole, in which R.sub.1 and R.sub.2 are independently selected from hydrogen and lower alkyl; ora pharmaceuticall |
| 5427684 |
Dialysis membrane composed of polysaccharide ether II |
June 27, 1995 |
| A dialysis membrane for hemodialysis in the form of sheet films, tubular films, or hollow fibers is composed of a polysaccharide ether. The polysaccharide ether has a structure given by the formula ##STR1## in which cell is the skeleton of the unmodified cellulose molecule or of |
| 5424398 |
Peptides and nucleic acid sequences related to the Epstein Barr virus |
June 13, 1995 |
| The present invention relates to peptides immunochemically reactive with antibodies to the Epstein-Barr virus (EBV), comprising at least part of the VCA-p18 or VCA-p40 protein, encoded within the EBV open reading frames BFRF3 and BdRF1 respectively, or a functional variant thereof. The |
| 5418228 |
Contraceptive regimen |
May 23, 1995 |
| A contraceptive method and regimen utilizing an initially greater amount of progestogen, which gradually tapers over the period in which the contraceptive is administered. The regimen includes a multiphasic combination and contraceptive kit containing at least 21 daily sequential dos |
| 5418226 |
Monoquaternary 2,16-bispiperidinylandrostane derivatives |
May 23, 1995 |
| Monoquaternary 2,16-bispiperidinylandrostane neuromuscular blocking derivatives having the formula: ##STR1## wherein R.sub.1 is ethyl;R.sub.2 is methyl or allyl; andX.sup.- is a pharmaceutically acceptable anion; or pharmaceutically acceptable salts thereof. |
| 5418044 |
Irreversibly stretchable laminate comprising layers of woven or knitted fabrics and water-vapor |
May 23, 1995 |
| In laminates composed of a woven or knitted fabric and a film impermeable to water and permeable to water vapor, the woven or knitted fabric is made of unstretched or partially stretched fibers. The laminates are highly extensible and retain the shape obtained by stretching. They are |
| 5416079 |
21-chloro-pregnane derivative |
May 16, 1995 |
| The invention is related to a 21-chloro-pregnane derivative of the formula ##STR1## or pharmaceutically acceptable salts thereof. The compound has intravenous anaesthetic activity, short onset time and high potency. |
| 5413919 |
Method for preparing from cultured cells a thromboplastic reagent suitable for use in the prothr |
May 9, 1995 |
| A method for preparing a thromboplastin reagent from cultured human cells comprising the steps of washing the cells with isotonic aqueous salt solution, lysing the cells by hypotonic shock, and resuspending the cell lysate in a diluent compatible with a one-stage prothrombin time det |
| 5407912 |
Method of treating bladder cancer with a keyhole limpet hemocyanin composition with enhanced ant |
April 18, 1995 |
| The present invention is directed to a stabilized keyhole limpet hemocyanin (KLH) composition in which (i) its intact non-degraded subunit is approximately 400,000 in molecular weight based on SDS-PAGE analysis; and (ii) are contained at least about 50% didecameric or higher KLH multimer |
| 5405324 |
Implantation device |
April 11, 1995 |
| The invention relates to an implantation device with which a medicinal implant can be introduced subcutaneously in humans or animals. The device comprises a hollow needle and a mandrel having a chamfered distal end, which precisely coincides with the plane of the chamfered distal end of |
| 5403485 |
Dialysis membrane made of cellulose acetate |
April 4, 1995 |
| A dialysis membrane in the form of a hollow fiber with a continuous internal cavity is made of cellulose acetate or a cellulose acetate derivative. The hollow fiber is made by using a gas to form the internal hollow cavity. A dialysis membrane in the form of a hollow fiber with a con |
| 5395627 |
Pharmaceutical granulate |
March 7, 1995 |
| Disclosed is a process of preparing granules involving first preparing a carrier comprising diluent, binder, and optionally a disintegrating agent. In a container separate from said carrier, asteroid, lubricant and, optionally, an antioxidant are dissolved in an, optionally pre-heated, |
| 5395545 |
Cleaning solution for automated analyzers |
March 7, 1995 |
| This invention relates to a novel cleaning solution for use particularly with automated analyzers used in clinical laboratories and a method of cleaning a surface with the novel cleaning solution. This solution eliminates problems of cross contamination of samples due to reagent carr |
| 5393759 |
Isochromane derivatives |
February 28, 1995 |
| The invention concerns an isochromane derivative having the general formula I ##STR1## in which R.sub.1 is one to four substituents independently selected from hydrogen, hydroxy, alkyl (1-4 C), alkoxy (1-4 C), halogen, or CF.sub.3, or as two adjacent substituents together a methy |
| 5389379 |
Process for the preparation of biologically active material containing polymeric microcapsules |
February 14, 1995 |
| A process for the preparation of microcapsules containing biologically active material is disclosed. The process involves dissolving a polymer into a solvent into which the active material is also introduced; atomizing the resulting suspension or solution and collecting the droplets |
| 5387345 |
Cellulose acetate membranes |
February 7, 1995 |
| A dialysis membrane in the form of a hollow fiber with a continuous internal cavity is made of cellulose acetate or a cellulose acetate derivative. The membrane has a maximum sieving coefficient of 0.04 for albumin with a molecular weight of 68,000. A dialysis membrane in the form of |
| 5385824 |
Method for detection of anti-RNA-antibodies |
January 31, 1995 |
| Method for monitoring patients having connective tissue autoimmune diseases comprising contacting patient specimens with (U1)RNA and detecting immune complexes formed, the level of reaction indicating the severity of the disease. |
